MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...

伦敦和纽约 - 临床阶段基因医学公司MeiraGTx Holdings plc (NASDAQ:MGTX)宣布其最新临床试验MGT-GAD-025取得令人鼓舞的结果。该试验旨在治疗帕金森氏症,达到了主要的安全性和耐受性目标,同时在特发性帕金森氏症患者的关键疗效终点上也显示出显著改善。

On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.

MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) ...

MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...

The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.

According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local production of GABA, a neurotransmitter that can help restore more normal ...

Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...

Gene therapy specialist Meiragtx Holdings plc got a market bump courtesy of newly released top-line data from its phase II bridging study in Parkinson’s disease. The six-month, three-arm randomized, ...

MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line ...

Piper Sandler重申了对MeiraGTx Holdings plc (NASDAQ: MGTX)股票的"增持"评级，目标价保持在$26.00。 尽管股价年初至今大幅下跌，但Piper Sandler认为，鉴于公司目前约$2.43亿的企业价值和潜在的大额里程碑付款，这是投资者的一个具有吸引力的入场点。